SEC Form 4 · accession 0001140361-17-025792
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew P. Young
Director
Period of report
Jun 20, 2017
Accepted (ET)
Jun 22, 2017 · 2:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.78 | Jun 20, 2017 | A | 14,000 | A | — | Jun 19, 2027 | Common Stock | 14,000 | 14,000 | D |
Explanation of responses
- F1The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date.